Who are Switch ticagrelor to clopidogrel's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Standard-DAPT of Ticagrelor plus aspirin, Aspirin + Ticagrelor, Blinded clopidogrel, Aspirin and clopidogrel / Prasugrel, prasugrel / clopidogrel, Aspirin combined with clopidogrel.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/switch-ticagrelor-to-clopidogrel.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Switch ticagrelor to clopidogrel — Competitive Intelligence Brief

Switch ticagrelor to clopidogrel (Switch ticagrelor to clopidogrel) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: P2Y12 receptor antagonist; antiplatelet agent. Area: Cardiovascular.

marketed P2Y12 receptor antagonist; antiplatelet agent P2Y12 receptor Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Switch ticagrelor to clopidogrel (Switch ticagrelor to clopidogrel) — The First Affiliated Hospital with Nanjing Medical University. Clopidogrel is a P2Y12 platelet adenosine diphosphate receptor antagonist that irreversibly inhibits platelet aggregation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Switch ticagrelor to clopidogrel TARGET	Switch ticagrelor to clopidogrel	The First Affiliated Hospital with Nanjing Medical University	marketed	P2Y12 receptor antagonist; antiplatelet agent	P2Y12 receptor
Standard-DAPT of Ticagrelor plus aspirin	Standard-DAPT of Ticagrelor plus aspirin	Second Affiliated Hospital, School of Medicine, Zhejiang University	marketed	Dual antiplatelet therapy (DAPT); P2Y12 inhibitor + cyclooxygenase inhibitor	P2Y12 receptor (ticagrelor); cyclooxygenase-1 (aspirin)
Aspirin + Ticagrelor	Aspirin + Ticagrelor	The First Affiliated Hospital with Nanjing Medical University	marketed	Dual antiplatelet agent	COX-1 (aspirin); P2Y12 receptor (ticagrelor)
Blinded clopidogrel	Blinded clopidogrel	VA Office of Research and Development	marketed	Antiplatelet agents	P2Y12 receptor
Aspirin and clopidogrel / Prasugrel	Aspirin and clopidogrel / Prasugrel	Assistance Publique - Hôpitaux de Paris	marketed	Antiplatelet agent (dual therapy combination)	COX-1 (aspirin); P2Y12 receptor (clopidogrel/prasugrel)
prasugrel / clopidogrel	prasugrel / clopidogrel	Assistance Publique - Hôpitaux de Paris	marketed	P2Y12 receptor antagonist (thienopyridine)	P2Y12 receptor
Aspirin combined with clopidogrel	Aspirin combined with clopidogrel	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	marketed	Dual antiplatelet agent	Cyclooxygenase (COX) and P2Y12 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (P2Y12 receptor antagonist; antiplatelet agent class)

The First Affiliated Hospital with Nanjing Medical University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Switch ticagrelor to clopidogrel — Competitive Intelligence Brief. https://druglandscape.com/ci/switch-ticagrelor-to-clopidogrel. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab